{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:51:00Z","timestamp":1787003460157,"version":"build-2736575974"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH\/NCI","award":["CA140182"],"award-info":[{"award-number":["CA140182"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Current treatment options for patients with pancreatic cancer are suboptimal, resulting in a five year survival rate of about 9%. Difficulties with treatment are due to an immunosuppressive, fibrotic tumor microenvironment that prevents drugs from reaching tumor cells, but also to the limited efficacy of existing FDA-approved chemotherapeutic compounds. We here show that the nucleoside analog Sangivamycin and its closely-related compound Toyocamycin target PDA cell lines, and are significantly more efficient than Gemcitabine. Using KINOMEscan screening, we identified the kinase Haspin, which is overexpressed in PDA cell lines and human PDA samples, as a main target for both compounds. Inhibition of Haspin leads to a decrease in Histone H3 phosphorylation and prevents Histone H3 binding to survivin, thus providing mechanistic insight of how Sangivamycin targets cell proliferation, mitosis and induces apoptotic cell death. In orthotopically implanted tumors in mice, Sangivamycin was efficient in decreasing the growth of established tumors. In summary, we show that Sangivamycin and derivatives can be an efficient new option for treatment of PDA.<\/jats:p>","DOI":"10.1038\/s41598-019-53223-0","type":"journal-article","created":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T06:03:18Z","timestamp":1573538598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Sangivamycin and its derivatives inhibit Haspin-Histone H3-survivin signaling and induce pancreatic cancer cell death"],"prefix":"10.1038","volume":"9","author":[{"given":"Ligia I.","family":"Bastea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laeticia M. A.","family":"Hollant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike R.","family":"D\u00f6ppler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Storz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,12]]},"reference":[{"key":"53223_CR1","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","volume":"74","author":"L Rahib","year":"2014","unstructured":"Rahib, L. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 74, 2913\u20132921, https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-0155 (2014).","journal-title":"Cancer Res"},{"key":"53223_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2018. CA Cancer J Clin 68, 7\u201330, https:\/\/doi.org\/10.3322\/caac.21442 (2018).","journal-title":"CA Cancer J Clin"},{"key":"53223_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.molcel.2015.11.006","volume":"60","author":"C Dominguez-Brauer","year":"2015","unstructured":"Dominguez-Brauer, C. et al. Targeting Mitosis in Cancer: Emerging Strategies. Mol Cell 60, 524\u2013536, https:\/\/doi.org\/10.1016\/j.molcel.2015.11.006 (2015).","journal-title":"Mol Cell"},{"key":"53223_CR4","doi-asserted-by":"publisher","first-page":"17049","DOI":"10.1074\/jbc.274.24.17049","volume":"274","author":"H Tanaka","year":"1999","unstructured":"Tanaka, H. et al. Identification and characterization of a haploid germ cell-specific nuclear protein kinase (Haspin) in spermatid nuclei and its effects on somatic cells. J Biol Chem 274, 17049\u201317057 (1999).","journal-title":"J Biol Chem"},{"key":"53223_CR5","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1101\/gad.1267105","volume":"19","author":"J Dai","year":"2005","unstructured":"Dai, J., Sultan, S., Taylor, S. S. & Higgins, J. M. The kinase haspin is required for mitotic histone H3 Thr 3 phosphorylation and normal metaphase chromosome alignment. Genes Dev 19, 472\u2013488, https:\/\/doi.org\/10.1101\/gad.1267105 (2005).","journal-title":"Genes Dev"},{"key":"53223_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1126\/science.1189505","volume":"330","author":"AE Kelly","year":"2010","unstructured":"Kelly, A. E. et al. Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science 330, 235\u2013239, https:\/\/doi.org\/10.1126\/science.1189505 (2010).","journal-title":"Science"},{"key":"53223_CR7","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1126\/science.1189435","volume":"330","author":"F Wang","year":"2010","unstructured":"Wang, F. et al. Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. Science 330, 231\u2013235, https:\/\/doi.org\/10.1126\/science.1189435 (2010).","journal-title":"Science"},{"key":"53223_CR8","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.cub.2011.05.016","volume":"21","author":"F Wang","year":"2011","unstructured":"Wang, F. et al. A positive feedback loop involving Haspin and Aurora B promotes CPC accumulation at centromeres in mitosis. Curr Biol 21, 1061\u20131069, https:\/\/doi.org\/10.1016\/j.cub.2011.05.016 (2011).","journal-title":"Curr Biol"},{"key":"53223_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1126\/science.1194498","volume":"330","author":"Y Yamagishi","year":"2010","unstructured":"Yamagishi, Y., Honda, T., Tanno, Y. & Watanabe, Y. Two histone marks establish the inner centromere and chromosome bi-orientation. Science 330, 239\u2013243, https:\/\/doi.org\/10.1126\/science.1194498 (2010).","journal-title":"Science"},{"key":"53223_CR10","unstructured":"Iimori, T. et al. A study on conformationally restricted sangivamycins and their inhibitory abilities of protein kinases. Nucleic Acids Symp Ser, 169\u2013170 (1992)."},{"key":"53223_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4014\/jmb.0910.10010","volume":"20","author":"J Kang","year":"2010","unstructured":"Kang, J., Lee, D. K. & Lee, C. H. Cell cycle arrest and cytochrome c-mediated apoptotic induction in human lung cancer A549 cells by MCS-C2, an analogue of sangivamycin. J Microbiol Biotechnol 20, 433\u2013437 (2010).","journal-title":"J Microbiol Biotechnol"},{"key":"53223_CR12","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1128\/AAC.30.5.719","volume":"30","author":"E De Clercq","year":"1986","unstructured":"De Clercq, E. & Robins, M. J. Xylotubercidin against herpes simplex virus type 2 in mice. Antimicrob Agents Chemother 30, 719\u2013724 (1986).","journal-title":"Antimicrob Agents Chemother"},{"key":"53223_CR13","first-page":"197","volume":"51","author":"JA Cavins","year":"1967","unstructured":"Cavins, J. A. et al. Initial toxicity study of sangivamycin (NSC-65346). Cancer Chemother Rep 51, 197\u2013200 (1967).","journal-title":"Cancer Chemother Rep"},{"key":"53223_CR14","doi-asserted-by":"publisher","first-page":"4881","DOI":"10.18632\/oncotarget.2051","volume":"5","author":"W Chien","year":"2014","unstructured":"Chien, W. et al. Selective inhibition of unfolded protein response induces apoptosis in pancreatic cancer cells. Oncotarget 5, 4881\u20134894, https:\/\/doi.org\/10.18632\/oncotarget.2051 (2014).","journal-title":"Oncotarget"},{"key":"53223_CR15","first-page":"1005","volume":"34","author":"CT Hardesty","year":"1974","unstructured":"Hardesty, C. T., Chaney, N. A., Waravdekar, V. S. & Mead, J. A. The disposition of the antitumor agent, sangivamycin, in mice. Cancer Res 34, 1005\u20131009 (1974).","journal-title":"Cancer Res"},{"key":"53223_CR16","first-page":"76","volume":"30","author":"HF Bisel","year":"1970","unstructured":"Bisel, H. F., Ansfield, F. J., Mason, J. H. & Wilson, W. L. Clinical studies with tubercidin administered by direct intravenous injection. Cancer Res 30, 76\u201378 (1970).","journal-title":"Cancer Res"},{"key":"53223_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.ccr.2006.03.019","volume":"9","author":"DR Carrasco","year":"2006","unstructured":"Carrasco, D. R. et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 9, 313\u2013325, https:\/\/doi.org\/10.1016\/j.ccr.2006.03.019 (2006).","journal-title":"Cancer Cell"},{"key":"53223_CR18","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1038\/onc.2011.335","volume":"31","author":"D Huertas","year":"2012","unstructured":"Huertas, D. et al. Antitumor activity of a small-molecule inhibitor of the histone kinase Haspin. Oncogene 31, 1408\u20131418, https:\/\/doi.org\/10.1038\/onc.2011.335 (2012).","journal-title":"Oncogene"},{"key":"53223_CR19","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1083\/jcb.201205119","volume":"199","author":"A De Antoni","year":"2012","unstructured":"De Antoni, A., Maffini, S., Knapp, S., Musacchio, A. & Santaguida, S. A small-molecule inhibitor of Haspin alters the kinetochore functions of Aurora B. J Cell Biol 199, 269\u2013284, https:\/\/doi.org\/10.1083\/jcb.201205119 (2012).","journal-title":"J Cell Biol"},{"key":"53223_CR20","doi-asserted-by":"publisher","unstructured":"Koutsioumpa, M. et al. Lysine methyltransferase 2D regulates pancreatic carcinogenesis through metabolic reprogramming. Gut, https:\/\/doi.org\/10.1136\/gutjnl-2017-315690 (2018).","DOI":"10.1136\/gutjnl-2017-315690"},{"key":"53223_CR21","doi-asserted-by":"publisher","first-page":"20198","DOI":"10.1073\/pnas.0901989106","volume":"106","author":"J Eswaran","year":"2009","unstructured":"Eswaran, J. et al. Structure and functional characterization of the atypical human kinase haspin. Proc Natl Acad Sci USA 106, 20198\u201320203, https:\/\/doi.org\/10.1073\/pnas.0901989106 (2009).","journal-title":"Proc Natl Acad Sci USA"},{"key":"53223_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-9-63","volume":"9","author":"LH Stockwin","year":"2009","unstructured":"Stockwin, L. H. et al. 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC Cancer 9, 63, https:\/\/doi.org\/10.1186\/1471-2407-9-63 (2009).","journal-title":"BMC Cancer"},{"key":"53223_CR23","doi-asserted-by":"publisher","first-page":"3264","DOI":"10.1158\/0008-5472.CAN-05-3940","volume":"66","author":"SK Radhakrishnan","year":"2006","unstructured":"Radhakrishnan, S. K. & Gartel, A. L. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity. Cancer Res 66, 3264\u20133270, https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-3940 (2006).","journal-title":"Cancer Res"},{"key":"53223_CR24","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/jso.25253","volume":"118","author":"L Zhou","year":"2018","unstructured":"Zhou, L. et al. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma. J Surg Oncol 118, 1115\u20131121, https:\/\/doi.org\/10.1002\/jso.25253 (2018).","journal-title":"J Surg Oncol"},{"key":"53223_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0076-6879(07)00401-6","volume":"439","author":"N Radulovich","year":"2008","unstructured":"Radulovich, N., Qian, J. Y. & Tsao, M. S. Human pancreatic duct epithelial cell model for KRAS transformation. Methods Enzymol 439, 1\u201313, https:\/\/doi.org\/10.1016\/S0076-6879(07)00401-6 (2008).","journal-title":"Methods Enzymol"},{"key":"53223_CR26","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1158\/1535-7163.MCT-14-0945","volume":"14","author":"S Borges","year":"2015","unstructured":"Borges, S. et al. Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101. Mol Cancer Ther 14, 1306\u20131316, https:\/\/doi.org\/10.1158\/1535-7163.MCT-14-0945 (2015).","journal-title":"Mol Cancer Ther"},{"key":"53223_CR27","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nbt1068","volume":"23","author":"MA Fabian","year":"2005","unstructured":"Fabian, M. A. et al. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23, 329\u2013336, https:\/\/doi.org\/10.1038\/nbt1068 (2005).","journal-title":"Nat Biotechnol"},{"key":"53223_CR28","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/nbt1358","volume":"26","author":"MW Karaman","year":"2008","unstructured":"Karaman, M. W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 26, 127\u2013132, https:\/\/doi.org\/10.1038\/nbt1358 (2008).","journal-title":"Nat Biotechnol"},{"key":"53223_CR29","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1016\/j.celrep.2016.02.029","volume":"14","author":"GY Liou","year":"2016","unstructured":"Liou, G. Y. et al. Mutant KRas-Induced Mitochondrial Oxidative Stress in Acinar Cells Upregulates EGFR Signaling to Drive Formation of Pancreatic Precancerous Lesions. Cell Rep 14, 2325\u20132336, https:\/\/doi.org\/10.1016\/j.celrep.2016.02.029 (2016).","journal-title":"Cell Rep"},{"key":"53223_CR30","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1158\/0008-5472.CAN-18-1153","volume":"79","author":"LI Bastea","year":"2019","unstructured":"Bastea, L. I. et al. Pomalidomide Alters Pancreatic Macrophage Populations to Generate an Immune-Responsive Environment at Precancerous and Cancerous Lesions. Cancer Res 79, 1535\u20131548, https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1153 (2019).","journal-title":"Cancer Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53223-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53223-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T10:54:33Z","timestamp":1671274473000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53223-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53223"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53223-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,12]]},"assertion":[{"value":"1 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16588"}}